September’s FDA advisory committee line-up

FDA advisory committees will meet in September to discuss an ALS therapy, treatments targeting three different cancer types, and a potential first-in-class biotherapeutic for C. difficile.

On Sept. 7, the Peripheral and Central Nervous System Drugs advisory committee will meet for the second time to discuss the NDA from Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) for AMX0035 to treat amyotrophic lateral sclerosis...